As of April 19, 2017, precertification requirements went
into effect for all commercial and Medicare Advantage members for the drugs
Spinraza (nusinersen) and Bavencio (avelumab).
We are in the process of updating the medical policies that address
Bavencio. In the interim, requests for Bavencio will be evaluated in accordance
with the manufacturer?s prescribing information and the U.S. Food and Drug
Administration labeling.
More information about Spinraza can be found in the following medical
policies:
- Commercial: #08.01.36: Nusinersen (Spinraza™)
- Medicare Advantage: #MA08.086: Nusinersen (Spinraza™
)
To view these policies, go to the Medical Policy Portal,
select Accept and Go to Medical Policy Online, then select
Commercial or Medicare Advantage, and type the policy name or
number in the Search field.
A comprehensive list of all drugs and services that require precertification is
available online for Independence
commercial members and
Medicare Advantage members.